New antibody versus standard immunotherapy for head and neck cancer
Treatments studied
This trial compares a new antibody treatment (INCA33890) with an existing immunotherapy (pembrolizumab) for certain head and neck cancers that have not been treated yet. The goal is to see if the new drug works better and is safe.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have squamous cell carcinoma of the head and neck that has not spread to other parts of the body and has not been treated before.
- Your doctor plans to treat the cancer with surgery, and you are between 18 and 75 years old.
- Your tumor tests positive for a protein called PD-L1 (a score of at least 1).
- You do not have serious heart, lung, or nervous system conditions, or an autoimmune disease.
- You have not had an organ transplant and are not taking steroids or other immunosuppressive treatments.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This Phase 2 study tests pembrolizumab (an immunotherapy medicine) together with induction chemotherapy before the main cancer treatment for stage III/IVA head and neck squamous cell cancer. It aims to improve how well the tumor responds and how long people can stay controlled.
This trial studies whether adding pembrolizumab (an immune system medicine) to radiation can improve outcomes in people newly diagnosed with metastatic head and neck squamous cell cancer. It may help the immune system better recognize and fight the cancer alongside radiation.
This trial compares two immunotherapy drugs (ivonescimab and pembrolizumab) given with standard chemotherapy before and possibly after surgery for advanced head and neck cancer that can be removed. The aim is to see which drug is better at shrinking the tumor and improving outcomes.
This trial combines two drugs (sintilimab, an immunotherapy, and nimotuzumab, an EGFR-targeting therapy) before and during standard chemoradiation, to see if it improves outcomes for people with advanced head and neck cancer. The hope is that adding these targeted treatments will make the cancer more responsive to radiation and chemotherapy.
This trial tests a combination of two drugs (CADI-05 and pembrolizumab) before surgery for people with a certain type of head and neck cancer that hasn't spread. The goal is to see if this treatment can help shrink the tumor before it is removed.
This trial tests whether giving immunotherapy along with chemotherapy before surgery can help treat locally advanced head and neck cancer that can be removed. The goal is to see if this combination shrinks tumors and improves outcomes.
Hear when a new Resectable Locally Advanced Head and Neck Squamous Cell Carcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.